Vixotrigine

Vixotrigine
Clinical data
Other names	Raxatrigine; CNV1014802; GSK-1014802; BIIB 074
Routes of; administration	By mouth
ATC code	None;
Identifiers
	IUPAC name (2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide;
CAS Number	934240-30-9 ; 934240-35-4 (mesylate);
PubChem CID	16046068;
ChemSpider	13174481;
UNII	QQS4J85K6Y;
KEGG	D11179;
CompTox Dashboard (EPA)	DTXSID901031867 ;
Chemical and physical data
Formula	C18H19FN2O2
Molar mass	314.360 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(NC1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N;
	InChI InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1; Key:JESCETIFNOFKEU-SJORKVTESA-N;

Vixotrigine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), formerly known as raxatrigine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).^[1]^[2]^[3] Vixotrigine was originally claimed to be a selective central Na_v1.3 blocker, but was subsequently redefined as a selective peripheral Na_v1.7 blocker.^{[citation needed]} Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker.^{[citation needed]} As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain.^[4] It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.^[4]

Quick facts Clinical data, Other names ...

See also